首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release
【2h】

Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release

机译:在基于PLGA的微球中灭活的脊髓灰质炎疫苗的热稳定性用于脉冲释放

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vaccines are a critical clinical tool in preventing illness and death due to infectious diseases and are regularly administered to children and adults across the globe. In order to obtain full protection from many vaccines, an individual needs to receive multiple doses over the course of months. However, vaccine administration in developing countries is limited by the difficulty in consistently delivering a second or third dose, and some vaccines, including the inactivated polio vaccine (IPV), must be injected more than once for efficacy. In addition, IPV does not remain stable over time at elevated temperatures, such as those it would encounter over time in the body if it were to be injected as a single-administration vaccine. In this manuscript, we describe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course of several weeks. Additionally, pH-sensitive, cationic dopants such as Eudragit E polymer caused clinically relevant amounts of stable IPV release upon degradation of the PLGA matrix. Specifically, IPV was released in two separate bursts, mimicking the delivery of two boluses approximately one month apart. In one of our top formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively, were released within the first few days from 50 mg of particles. During the delayed, second burst, 0.5, 0.8, and 0.6 doses of each serotype, respectively, were released; thus, 50 mg of these particles released approximately two clinical doses spaced a month apart. Immunization of rats with the leading microsphere formulation showed more robust and long-lasting humoral immune response compared to a single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month apart. By minimizing the number of administrations of a vaccine, such as IPV, this technology can serve as a tool to aid in the eradication of polio and other infectious diseases for the improvement of global health.
机译:疫苗是预防因传染病引起的疾病和死亡的重要临床工具,并定期向全球儿童和成人给药。为了获得对许多疫苗的全面保护,一个人需要在几个月的时间内接受多次剂量。但是,发展中国家的疫苗管理受到持续提供第二或第三剂疫苗的困难的限制,并且某些疫苗(包括灭活的脊髓灰质炎疫苗(IPV))必须注射多次才能有效。另外,IPV在升高的温度下不会随时间保持稳定,例如,如果将其作为单次注射疫苗注射会在体内随时间推移而遇到。在本手稿中,我们描述了由聚乳酸-乙醇酸共聚物(PLGA)组成的微球,该微球可以封装IPV以及稳定的赋形剂,并在数周的过程中释放出免疫原性IPV。另外,pH敏感的阳离子掺杂剂(例如Eudragit E聚合物)在PLGA基质降解后引起临床上相当数量的稳定IPV释放。具体来说,IPV分两次释放,模仿了大约一个月间隔两次推注的情况。在我们最常用的配方之一中,在最初几天内从50 mg颗粒中分别释放了1.4、1.1和1.2剂量的IPV血清型1、2和3。在延迟的第二次爆发期间,每种血清型分别释放了0.5、0.8和0.6剂剂量。因此,这些颗粒中的50 mg释放了大约两个临床剂量,间隔一个月。与单次大剂量注射相比,采用领先的微球制剂对大鼠的免疫显示出更强大和更持久的体液免疫反应,并且在统计学上不比间隔1个月的两次大剂量注射差。通过最大程度地减少疫苗(如IPV)的给药次数,该技术可以用作帮助根除脊髓灰质炎和其他传染性疾病以改善全球健康的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号